Valuation: Alkermes plc

Market Cap 8.6B 7.5B 6.92B 6.35B 12.07B 828B 12.28B 82.44B 32.37B 404B 32.29B 31.59B 1,394B P/E 2026 *
-135x
P/E 2027 * 88.6x
Enterprise Value 9.61B 8.38B 7.73B 7.1B 13.49B 925B 13.71B 92.11B 36.17B 452B 36.08B 35.29B 1,557B EV / Sales 2026 *
5.31x
EV / Sales 2027 * 4.95x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day+0.74%
1 week-5.87%
Current month-0.79%
1 month+17.39%
3 months+53.47%
6 months+69.76%
Current year+85.78%
1 week 50.49
Extreme 50.4855
54.9
1 month 43.43
Extreme 43.43
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 31/01/1991
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer 58 29/05/2017
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 74 25/05/2016
Director/Board Member 63 29/03/2018
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

Compliance Officer

-2,034 0.0012%
06-30Fiscal year

Chief Technology Officer

19,000 0.0114%
06-11Sell

Director

-2,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+0.74%-5.87%+75.08%+70.76% 8.6B
-0.17%+1.22%+2.98%+6.80% 50.35B
-0.29%-3.16%+380.69%+591.82% 39.32B
-0.49%-0.68%+29.15%-6.46% 34.69B
+1.53%+0.74%+23.45%+58.54% 34.08B
+1.68%-1.40%+4.23%+27.34% 26.63B
+1.13%+0.60% - - 16.49B
-1.29%-3.12%+65.20%+117.60% 15.31B
+0.43%+0.55%+15.19%+17.46% 13.8B
+2.45%+1.99%+15.09%-30.12% 12.87B
Average +0.57%-1.02%+67.89%+94.86% 25.21B
Weighted average by Cap. +0.41%-0.53%+81.01%+120.42%

Financials

2026 *2027 *
Net sales 1.81B 1.58B 1.46B 1.34B 2.54B 174B 2.58B 17.34B 6.81B 85.06B 6.79B 6.64B 293B 1.89B 1.65B 1.52B 1.4B 2.65B 182B 2.7B 18.11B 7.11B 88.84B 7.1B 6.94B 306B
Net income -64.46M -56.22M -51.88M -47.6M -90.49M -6.2B -92M -618M -243M -3.03B -242M -237M -10.45B 99.47M 86.76M 80.07M 73.47M 140M 9.57B 142M 954M 374M 4.68B 374M 365M 16.12B
Net Debt 1.01B 880M 812M 745M 1.42B 97.05B 1.44B 9.67B 3.8B 47.41B 3.79B 3.7B 163B 757M 661M 610M 559M 1.06B 72.89B 1.08B 7.26B 2.85B 35.61B 2.84B 2.78B 123B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
15/07/26 US$51.98 +0.74% 1,556,151
14/07/26 US$51.60 -0.52% 1,776,619
13/07/26 US$51.87 -0.13% 1,583,838
10/07/26 US$51.94 -3.42% 1,691,454
09/07/26 US$53.78 -0.94% 1,630,543
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
51.60USD
Average target price
51.59USD
Spread / Average Target
-0.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock